BSE filing, NSE: LAURUSLABS. Summary written from the filing by ALFA Finder's alert engine.
Laurus Labs Ltd: key numbers
- Share price
- ₹2,181.90
- Market cap
- ₹1,17,891 Cr
- Revenue (annual)
- ₹6,813 Cr
- Net profit (annual)
- ₹888.8 Cr
- P/E (TTM)
- 107.8×Sector 46.1×
- Promoter holding
- 27.47%+0.00% QoQ
- FII holding
- 30.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Laurus Labs Ltd
All →Laurus Labs Other Announcement
Laurus Labs Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Laurus Labs Acquisition Worth ₹107.8 Cr
Laurus Labs has invested ₹107.80 Crore in its joint venture, KRKA Pharma Private Limited, through a rights issue. The company maintains its 49% stake.
- Value
- ₹107.8 Cr
Laurus Labs Board Meeting Date
Laurus Labs scheduled a board meeting on October 29, 2026, to consider quarterly financial results and a proposal for an interim dividend for FY 2026-27.
Laurus Labs Other Announcement
Laurus Labs has submitted the Regulation 74(5) certificate for the quarter ended September 30, 2026, confirming the dematerialization and rematerialization of its securities.
Laurus Labs Acquisition Worth ₹12.1 Cr
Laurus Labs invested ₹12.10 Crore in Kurnool Renewables Private Limited via a rights issue, maintaining its 26% shareholding stake.
- Value
- ₹12.10 Cr
Laurus Labs Investor Presentation: Key Takeaways
Laurus Labs delivered record Q1FY27 revenue of ₹2,026 Cr, a 29% YoY increase, driven by robust CDMO growth. EBITDA margins expanded 700 bps YoY to 31.8% on favorable mix.
Other employee stock options announcements
All →RateGain Travel Technologies Employee Stock Options
RateGain granted 53,021 Stock Appreciation Rights under its SAR Scheme 2022 at ₹800 and ₹862.25 per unit. The grants vest over four years and are exercisable within three years of vesting.
- Execution
- Vesting over 4 years (10% Y1, 20% Y2, 30% Y3, 40% Y4); exercisable within 3 years of vesting
Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.